Event time: 事件时间：
Published: 文章发布：
Key Results
Actual vs Consensus
EPS: $2.39 vs $2.30 estimate, beat+3.9%.Revenue: $493M vs $492M estimate, in line+0.3%.Profitability and Cash Flow
Period: 2026 Q3 period ended 2026-09-30Revenue: $493M; YoY: +39.2%; QoQ: +2.5%Gross profit: $410M; Gross margin: 83.3%Operating income: $295M; Operating margin: 59.8%; YoY: +35.4%; QoQ: +2.5%Net income: $247M; GAAP diluted EPS: $2.01; YoY: +41.0%; QoQ: +7.5%Operating cash flow: $258M; Capex: $3M; Free cash flow: $255MCash: $1.0B; Total debt: $306M; Net cash: $724MOfficial release: HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
核心结果
实际值与市场预期
EPS：$2.39 vs $2.30 预期，高于预期+3.9%。营收：$493M vs $492M 预期，基本符合预期+0.3%。财务指标
期间：2026 Q3（截至 2026-09-30）营收：$493M；同比：+39.2%；环比：+2.5%毛利润：$410M；毛利率：83.3%经营利润：$295M；经营利润率：59.8%；同比：+35.4%；环比：+2.5%净利润：$247M；GAAP 稀释 EPS：$2.01；同比：+41.0%；环比：+7.5%经营现金流：$258M；资本开支：$3M；自由现金流：$255M现金：$1.0B；总债务：$306M；净现金：$724M
